Horizant Approved to Treat Restless Legs Syndrome

Possible side effects include drowsiness and dizziness

THURSDAY, April 7 (HealthDay News) -- Horizant extended release tablets (gabapentin enacarbil) have been approved as a once-daily treatment for restless legs syndrome (RLS).

Horizant was evaluated in a pair of 12-week trials among adults with moderate-to-severe RLS. People who took the drug reported improvement in RLS symptoms compared to those who took a placebo.

The drug's common side effects include drowsiness and dizziness. The body absorbs Horizant as gabapentin, a drug used to treat epilepsy. Horizant's label will include a warning that drugs used to treat epilepsy may lead to suicidal thoughts and actions in some people, the FDA said.

Horizant was developed by drugmakers GlaxoSmithKline and Xenoport.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about restless legs syndrome.

Physician's Briefing